Fennec Pharmaceuticals (FENC) Accounts Payables (2010 - 2025)

Fennec Pharmaceuticals' Accounts Payables history runs 16 years deep, the most recent figure standing at $4.6 million for Q4 2025.

• Quarterly Accounts Payables rose 43.01% year-over-year to $4.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.6 million (up 43.01% YoY) and the FY2025 annual result came in at $4.6 million, up 43.01% from the prior year.
• Accounts Payables was $4.6 million for Q4 2025 at Fennec Pharmaceuticals, down from $5.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $5.9 million in Q2 2025 and bottomed at $677000.0 in Q2 2021.
• A 5-year average of $3.2 million and a median of $3.0 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2021 — Accounts Payables tumbled 75.43% — and 2022, when it surged 207.59%.
• Fennec Pharmaceuticals' Accounts Payables stood at $777000.0 in 2021, then jumped by 207.59% to $2.4 million in 2022, then jumped by 58.08% to $3.8 million in 2023, then retreated by 14.21% to $3.2 million in 2024, then soared by 43.01% to $4.6 million in 2025.
• Business Quant data shows FENC's Accounts Payables at $4.6 million in Q4 2025, $5.9 million in Q3 2025, and $5.9 million in Q2 2025.